Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

About the trial

Sponsor

Luminopia

Tested

N/A this is an observational study of Standard of Care (device)

Dates

Started 2023-09-01; completion 2026-12-31

Results posted

Not yet

Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first time since the incorporation of atropine penalization into amblyopia management, physicians can now offer Luminopia, an FDA-approved dual action dichoptic treatment, to patients with amblyopia. Since…

From ClinicalTrials.gov, last updated 2025-09-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Luminopia, Inc. reported $34,184 in research payments for this study in 2025 (7 payments).

Products named: Luminopia

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.